Optiscan Imaging Begins Head, Neck Cancer Imaging Study in US
MT Newswires Live
5 hours ago
Optiscan Imaging (ASX:OIL) began a new US-based head and neck cancer imaging study on 35-patients to assess the performance of Optiscan's InVue and InForm imaging platforms in head and neck tumor resections, according to a Tuesday Australian bourse filing.
The InVue platform will be used during head and neck tumor resections to capture real-time, in vivo microscopic images within the surgical cavity following tumor removal. Following excision, tissue specimens will be analysed ex vivo using the InForm platform.
Patient recruitment was initiated at Mayo Clinic in Rochester.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.